2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Herceptin Adjuvant (HERA) Trial Study Team, Aron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, Evandro de Azambuja, Marion Procter, Thomas M Suter, Christian Jackisch, David Cameron, Harald A Weber, Dominik Heinzmann, Lissandra Dal Lago, Eleanor McFadden, Mitch Dowsett, Michael Untch, Luca Gianni, Richard Bell, Claus-Henning Köhne, Anita Vindevoghel, Michael AnderssonA Murray Brunt, Douglas Otero-Reyes, Santai Song, Ian Smith, Brian Leyland-Jones, Jose Baselga

Research output: Contribution to journalArticlepeer-review

Abstract

Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant trastuzumab, but the optimum duration of treatment is unknown. We compared 2 years of treatment with trastuzumab with 1 year of treatment, and updated the comparison of 1 year of trastuzumab versus observation at a median follow-up of 8 years, for patients enrolled in the HERceptin Adjuvant (HERA) trial.
Original languageEnglish
Pages (from-to)1021-8
Number of pages8
JournalThe Lancet
Volume382
Issue number9897
DOIs
Publication statusPublished - 21 Sep 2013

Keywords

  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Medication Adherence
  • Middle Aged
  • Receptor, erbB-2
  • Treatment Outcome

Fingerprint

Dive into the research topics of '2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial'. Together they form a unique fingerprint.

Cite this